摘要
目的探讨血清中微小RNA-542-3p(miR-542-3p)和组织中血管生成素-2(Ang-2)在甲状腺乳头状癌(PTC)患者中的表达及临床意义。方法选取2020年1月至2022年6月厦门市海沧医院的40例PTC患者作为PTC组,选取同期40例良性甲状腺疾病患者作为对照组。比较两组患者miR-542-3p和Ang-2阳性的表达,不同临床资料参数中miR-542-3p和Ang-2阳性的表达。分析miR-542-3p、Ang-2阳性与不同病理特征的相关性,并采用受试者工作特征(ROC)曲线分析其临床诊断价值。结果PCT组患者血清中的miR-542-3p水平低于对照组,组织中的Ang-2阳性表达率高于对照组,差异有统计学意义(P<0.05);PCT组患者术后血清中的miR-542-3p水平高于术前,差异有统计学意义(P<0.05);病灶最大径>1 cm以及发生淋巴转移患者血清中的miR-542-3p水平低于病灶最大径≤1 cm以及未发生淋巴转移PCT患者,组织中的Ang-2阳性表达率高于病灶最大径≤1 cm以及未发生淋巴转移的PCT患者,差异有统计学意义(P<0.05);Spearman相关性分析显示,血清中的miR-542-3p水平与PCT患者的病灶最大径、淋巴转移呈负相关(r=-0.581、-0.614,P<0.05),组织中的Ang-2阳性表达率与病灶最大径、淋巴转移呈正相关(r=0.587、0.593,P<0.05)。ROC曲线显示,血清中miR-542-3p与组织中Ang-2阳性表达率诊断PCT的曲线下面积(AUC)分别为0.789、0.888,采用miR-542-3p联合Ang-2诊断PCT的AUC及敏感度均高于单一指标诊断。结论与良性甲状腺疾病患者比较,PTC患者术前血清中的miR-542-3p表达下调,组织中Ang-2阳性表达率上调,术后血清miR-542-3p水平上调对评估手术疗效具有一定的价值。且血清中miR-542-3p、组织中Ang-2阳性表达率与PCT患者的病灶最大径和淋巴转移密切相关,术前血清miR-542-3p联合组织Ang-2阳性表达率诊断PTC具有较高临床价值,建议密切监测。
Objective To investigate the expression and clinical significance of microRNA-542-3p(miR-542-3p)in serum and angiopoietin-2(Ang-2)in tissues of patients with papillary thyroid carcinoma(PTC).Methods Forty patients with PTC admitted to Xiamen Haicang Hospital from January 2020 to June 2022 were selected as the PTC group,and 40 patients with benign thyroid disease in the same period were selected as the control group.The miR-542-3p and positive expression of Ang-2 in two groups of patients,miR-542-3p and positive expression of Ang-2 in different clinical data parameters were compared.The correlation between miR-542-3p,positive expression of Ang-2 and different pathological features was analyzed,the clinical diagnostic value was analyzed using the receiver operating characteristic(ROC)curve.Results The levels of miR-542-3p in the serum of patients in the PCT group was lower than that in the control group,and the positive expression rate of Ang-2 in the tissue was higher than that in the control group,the differences were statistically significant(P<0.05).The postoperative serum miR-542-3p levels in the PCT group was higher than that preoperative,the difference was statistically significant(P<0.05).The level of miR-542-3p in the serum of patients with maximum diameter of the lesion>1 cm and lymph node metastasis was lower than that of patients with maximum diameter of the lesion≤1 cm and PCT patients without lymph node metastasis,the positive expression rate of Ang-2 in tissues was higher than that of PCT patients with maximum lesion diameter≤1 cm and no lymph node metastasis,the differences were statistically significant(P<0.05).Spearman correlation analysis shows that the level of miR-542-3p in serum was negatively correlated with the maximum diameter of the lesion and lymph node metastasis in PCT patients (r=-0.581, -0.614, P<0.05), the positive expression rate of Ang-2 in tissues was positively correlated with the maximum diameter of the lesion and lymph node metastasis (r=0.587, 0.593, P<0.05). The ROC curve showed that the area under curve (AUC) of miR-542-3p in serum and Ang-2 positive expression rate in tissue for diagnosis of PCT were 0.789 and 0.888, respectively. The AUC and sensitivity of using miR-542-3p combined with Ang-2 positive expression rate to diagnose PCT was higher than that of single indicator diagnosis. Conclusion Compared with patients with benign thyroid disease, the expression of miR-542-3p in the serum of PTC patients is down regulate preoperative, and the positive expression rate of Ang-2 in the tissues is up regulate. The increase of the level of miR-542-3p in the serum postoperative has certain value in evaluating the surgical efficacy. Moreover, the positive expression rate of miR-542-3p in serum and Ang-2 in tissue is closely related to the maximum diameter of the lesion and lymph node metastasis in PCT patients. The combination of miR-542-3p in serum and Ang-2 positive expression rate in tissue preoperative has high clinical value in diagnosing PTC, and close monitoring is recommended.
作者
邱捷
郭久冰
QIU Jie;GUO Jiubing(Department of General Surgery,Xiamen Haicang Hospital,Fujian Province,Xiamen361000,China)
出处
《中国当代医药》
CAS
2023年第23期17-21,32,共6页
China Modern Medicine
基金
福建省厦门市海沧区科技计划项目(350205Z20202008)。
